John Sedor became the CEO of Pernix Therapeutics
Holdings Inc (NASDAQ:PTX) in 2016.
This analysis aims first to contrast CEO compensation with other
companies that have similar market capitalization. After that, we
will consider the growth in the business. And finally â as a second
measure of performance â we will look at the returns shareholders
have received over the last few years. This method should give us
information to assess how appropriately the company pays the
View our latest analysis
for Pernix Therapeutics Holdings
According to our data, Pernix Therapeutics
Holdings Inc has a market capitalization of US$7.0m, and pays its
CEO total annual compensation worth US$1.2m. (This is based on the
year to 2017). While we always look at total compensation first, we
note that the salary component is less, at US$610k. We looked at a
group of companies with market capitalizations under US$200m, and
the median CEO compensation was US$295k.
Thus we can conclude that John Sedor receives
more in total compensation than the median of a group of companies
in the same market, and of similar size to Pernix Therapeutics
Holdings Inc. However, this doesnât necessarily mean the pay is too
high. We can better assess whether the pay is overly generous by
looking into the underlying business performance.
You can see a visual representation of the CEO
compensation at Pernix Therapeutics Holdings, below.
On average over the last three years, Pernix
Therapeutics Holdings Inc has grown earnings per share (EPS) by 44%
each year. In the last year, its revenue is down -5.0%.
This shows that the company has improved itself
over the last few years. Good news for shareholders. The lack of
revenue growth isnât ideal, but it is the bottom line that counts
most in business.
We donât have analyst forecasts, but you could
get a better understanding of its growth by checking out this more detailed
historical graph of earnings, revenue and cash flow.
Since shareholders would have lost about 98% over
three years, some Pernix Therapeutics Holdings Inc shareholders
would surely be feeling negative emotions. So shareholders would
probably think the company shouldnât be too generous with CEO
We compared total CEO remuneration at Pernix
Therapeutics Holdings Inc with the amount paid at companies with a
similar market capitalization. As discussed above, we discovered
that the company pays more than the median of that group.
However we must not forget that the EPS growth
has been very strong over three years. Having said that,
shareholders may be disappointed with the weak returns over the
last three years. One might thus conclude that it would be better
if the company waited until growth is reflected in the share price,
before increasing CEO compensation. CEO compensation is one thing,
but it is also interesting to check if the CEO is buying
or selling Pernix Therapeutics Holdings (free visualization of
Or you could feast your eyes on
graph depicting past earnings, cash flow and
To help readers see past the short term
volatility of the financial market, we aim to bring you a long-term
focused research analysis purely driven by fundamental data. Note
that our analysis does not factor in the latest price-sensitive
The author is an independent contributor and at the time of
publication had no position in the stocks mentioned. For errors
that warrant correction please contact the editor at